Opthea to Present Wet AMD Trial Data
Ticker: OPTEY · Form: 6-K · Filed: Jun 3, 2024 · CIK: 1815620
Sentiment: neutral
Topics: clinical-trials, biotech, presentation
Related Tickers: OPT
TL;DR
Opthea (OPT) presenting Phase 3 wet AMD data at summit meeting, key for sozinibercept approval.
AI Summary
Opthea Limited (OPT) announced on June 3, 2024, that it will present at the Clinical Trials at the Summit Meeting. The presentation will focus on data from its Phase 3 clinical trials for its novel biologic therapy, sozinibercept, for the treatment of wet age-related macular degeneration (AMD). This event highlights the company's ongoing progress in advancing its lead drug candidate towards potential regulatory approval.
Why It Matters
This presentation provides an update on Opthea's key clinical trial data, which is crucial for investors and the medical community to assess the potential of sozinibercept in treating a significant unmet need in wet AMD.
Risk Assessment
Risk Level: medium — Clinical trial data presentations can influence investor sentiment and future stock performance, but the ultimate success depends on regulatory approval and market adoption.
Key Players & Entities
- Opthea Limited (company) — Registrant
- sozinibercept (drug) — Lead drug candidate
- wet age-related macular degeneration (AMD) (disease) — Target indication
- Clinical Trials at the Summit Meeting (event) — Presentation venue
- 001-39621 (filing_id) — SEC File Number
FAQ
What specific data from the Phase 3 trials will Opthea present?
The filing does not specify the exact data points to be presented, only that it will focus on data from its Phase 3 clinical trials for sozinibercept.
When is the Clinical Trials at the Summit Meeting scheduled to take place?
The filing does not provide the date of the meeting, only that Opthea will present during the month of June 2024.
What is the primary indication for sozinibercept?
Sozinibercept is being developed for the treatment of wet age-related macular degeneration (AMD).
What is Opthea Limited's SEC file number?
Opthea Limited's SEC file number is 001-39621.
Does Opthea file annual reports on Form 20-F or 40-F?
Opthea files annual reports on Form 20-F.
Filing Stats: 152 words · 1 min read · ~1 pages · Grade level 13.1 · Accepted 2024-06-03 06:04:43
Filing Documents
- opt_opthea_presents_at_c.htm (6-K) — 23KB
- opt-ex99_1.htm (EX-99.1) — 26KB
- img260626642_0.jpg (GRAPHIC) — 61KB
- img260626642_1.jpg (GRAPHIC) — 61KB
- 0000950170-24-067643.txt ( ) — 217KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. OPTHEA LIMITED (Registrant) By: /s/ Frederic Guerard Name: Frederic Guerard Title: Chief Executive Officer Date: 06/03/2024